Literature DB >> 34520322

Using PAMPs and DAMPs as adjuvants in cancer vaccines.

Huanyou Sun1, Wenwen Hu1, Yinan Yan1, Zichun Zhang1, Yuxin Chen1, Xuefan Yao1, Ling Teng1, Xinyuan Wang1, Dafei Chai1,2,3, Junnian Zheng2,3, Gang Wang1,2,3.   

Abstract

Immunotherapy for cancer has attracted considerable attention. As one of the immunotherapeutics, tumor vaccines exert great potential for cancer immunotherapy. The most important components in tumor vaccines are antigens and adjuvants, which determine the therapeutic safety and efficacy, respectively. After decades of research, many types of adjuvants have been developed. Although these adjuvants can induce strong and long-lasting immune responses in tumor immunity, they also cause more severe toxic side effects and are therefore not suitable for use in humans. With the development of innate immunity research, pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) are receiving more attention in vaccine design. However, whether they have the potential to become new adjuvants remains to be elucidated. The purpose of this review is to provide newideas for the research and development of new adjuvants by discussing the mechanisms and related functions of PAMPs and DAMPs.

Entities:  

Keywords:  Cancer; DAMPs; PAMPs; adjuvant; immunotherapy; tumor vaccine

Mesh:

Substances:

Year:  2021        PMID: 34520322      PMCID: PMC8903972          DOI: 10.1080/21645515.2021.1964316

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   4.526


  119 in total

Review 1.  Recognition of pathogen-associated molecular patterns by TLR family.

Authors:  Shizuo Akira; Hiroaki Hemmi
Journal:  Immunol Lett       Date:  2003-01-22       Impact factor: 3.685

Review 2.  DAMPs, PAMPs and alarmins: all we need to know about danger.

Authors:  Marco E Bianchi
Journal:  J Leukoc Biol       Date:  2006-10-10       Impact factor: 4.962

3.  Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses.

Authors:  Jing Wei Jin; Shun Qing Tang; Min Zhi Rong; Ming Qiu Zhang
Journal:  Acta Biomater       Date:  2018-08-09       Impact factor: 8.947

Review 4.  Overview of Vaccine Adjuvants: Introduction, History, and Current Status.

Authors:  Ruchi R Shah; Kimberly J Hassett; Luis A Brito
Journal:  Methods Mol Biol       Date:  2017

5.  Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination.

Authors:  P Fagone; D J Shedlock; H Bao; O U Kawalekar; J Yan; D Gupta; M P Morrow; A Patel; G P Kobinger; K Muthumani; D B Weiner
Journal:  Gene Ther       Date:  2011-05-05       Impact factor: 5.250

Review 6.  Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses.

Authors:  Moses O Oyewumi; Amit Kumar; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

7.  Helicobacter pylori Hp(2-20) promotes migration and proliferation of gastric epithelial cells by interacting with formyl peptide receptors in vitro and accelerates gastric mucosal healing in vivo.

Authors:  Amato de Paulis; Nella Prevete; Francesca W Rossi; Felice Rivellese; Fiamma Salerno; Gabriele Delfino; Bianca Liccardo; Elvira Avilla; Nunzia Montuori; Massimo Mascolo; Stefania Staibano; Rosa Marina Melillo; Giuseppe D'Argenio; Vittorio Ricci; Marco Romano; Gianni Marone
Journal:  J Immunol       Date:  2009-08-19       Impact factor: 5.422

8.  A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.

Authors:  Cornelia L Trimble; Shiwen Peng; Ferdynand Kos; Patti Gravitt; Raphael Viscidi; Elizabeth Sugar; Drew Pardoll; T C Wu
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

9.  Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellin.

Authors:  Karla L Lightfield; Jenny Persson; Sky W Brubaker; Chelsea E Witte; Jakob von Moltke; Eric A Dunipace; Thomas Henry; Yao-Hui Sun; Dragana Cado; William F Dietrich; Denise M Monack; Renée M Tsolis; Russell E Vance
Journal:  Nat Immunol       Date:  2008-08-24       Impact factor: 25.606

Review 10.  DAMPs from Cell Death to New Life.

Authors:  Emilie Vénéreau; Chiara Ceriotti; Marco Emilio Bianchi
Journal:  Front Immunol       Date:  2015-08-18       Impact factor: 7.561

View more
  3 in total

Review 1.  Rational Vaccinology: Harnessing Nanoscale Chemical Design for Cancer Immunotherapy.

Authors:  Ziyin Huang; Cassandra E Callmann; Shuya Wang; Matthew K Vasher; Michael Evangelopoulos; Sarah Hurst Petrosko; Chad A Mirkin
Journal:  ACS Cent Sci       Date:  2022-05-20       Impact factor: 18.728

2.  Calreticulin as an Adjuvant In Vivo to Promote Dendritic Cell Maturation and Enhance Antigen-Specific T Lymphocyte Responses against Melanoma.

Authors:  Zheng Gong; Ming Chen; Jie Miao; Chao-Jie Han; Qiao Zhong; Fang-Yuan Gong; Xiao-Ming Gao
Journal:  J Immunol Res       Date:  2022-08-09       Impact factor: 4.493

Review 3.  Tailor made magnetic nanolights: fabrication to cancer theranostics applications.

Authors:  Poushali Das; Sayan Ganguly; Shlomo Margel; Aharon Gedanken
Journal:  Nanoscale Adv       Date:  2021-10-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.